4-hydroxycyclophosphamide has been researched along with Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Hassan, M; Lundin, J; Nilsson, C; Olsson, H; Osterborg, A | 1 |
1 trial(s) available for 4-hydroxycyclophosphamide and Multiple Myeloma
| Article | Year |
|---|---|
The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Area Under Curve; Cyclophosphamide; Drug Interactions; Female; Humans; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Multiple Myeloma | 1999 |
1 other study(ies) available for 4-hydroxycyclophosphamide and Multiple Myeloma
| Article | Year |
|---|---|
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cells; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Mice, Inbred Strains; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Syndecan-1; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7; Tumor Stem Cell Assay | 2008 |